Researchers at Northwestern Medicine have identified immune system markers that may help predict which patients respond to BCG bladder cancer therapy and which do not, according to findings published in the Journal of Clinical Investigation. The discovery could lead to more personalized treatment for bladder cancer, one of the most common cancers worldwide.
BCG (Bacillus Calmette-Guérin) therapy is a standard immunotherapy for non-muscle invasive bladder cancer, but it fails in about 30–40% of patients. Currently, there is no reliable way to identify who will benefit. The new study highlights specific biomarkers in the immune system that correlate with treatment response, potentially allowing doctors to tailor therapy and avoid ineffective treatments.
The research is part of a broader push to refine immunotherapy approaches. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also working to advance immunotherapy techniques, though the Northwestern study focuses specifically on predictive markers rather than new treatments.
Bladder cancer affects approximately 550,000 new patients each year globally. For patients with non-muscle invasive bladder cancer, BCG therapy is often the first line of defense after surgery. If doctors could predict response, patients unlikely to benefit could be directed to alternative treatments sooner, potentially improving survival rates and reducing side effects.
The implications for the oncology field are significant: personalized immunotherapy based on immune markers could become a standard practice, reducing trial-and-error in treatment selection. This could also lower healthcare costs by avoiding ineffective therapies.
Further research is needed to validate these biomarkers in larger clinical trials before they can be adopted in routine practice. However, the study represents a step forward in understanding the immune mechanisms behind bladder cancer treatment response.
